In line with this, a subgroup of patients amounting to 42% of the PF-ILD cohort, which were characterised by dSSc, active disease, disease duration less than 1 year, decreased LFTs (FVC <80% and DLCO% <70%), respiratory symptoms, and immunosuppressive therapy naïve, had a notably higher concentration of ICAM1 + EVs and experienced PF-ILD already at 6 (6–12) months of follow up (Figure 5). This evidence concerns the gene ICAM1 and interstitial lung disease.